Addition of PCSK9 Inhibitors and Ezetimibe to Statin Therapy for Cardiovascular Risk Reduction
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis
BMJ 2022 May 04;377(xx)e069116, SU Khan, SH Yedlapati, AN Lone, Q Hao, G Guyatt, N Delvaux, GET Bekkering, PO Vandvik, IB Riaz, S Li, B Aertgeerts, N RodondiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.